SCRS Talks
SCRS Talks, hosted by the Society for Clinical Research Sites (SCRS), is a platform for clinical research industry professionals to hear about valuable information shaping the research industry today. These short interviews will provide new perspectives and insights on pressing topics, current events, and the research community.
SCRS Talks
Work Smarter, Not Harder: BD & Operations
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Lauren Stockwell sits down with Jennifer Larkin, VP of Business Development at M3 Wake Research, to break down what a modern site BD function actually looks like day to day. Jennifer walks through how data intelligence and AI platforms have reshaped feasibility and pipeline management, why relationships alone aren't predictive of future business, and the tiering framework she used to re-rank client accounts based on pipeline fit rather than tenure.
The conversation also covers what turns a sponsor-site relationship from transactional to genuinely partnered, why sites should be willing to say no, and the specific metrics, from proposal-to-award conversion to time from award to first patient screened, that reveal whether a BD strategy is actually working.
Welcome to SCRS Talks. I'm Lauren Stockwell, the associate director of education and engagement at SCRS. And today, we're joined by Jennifer Larkin, vice president of business development at M3 Wake Research. Today, we get the privilege of deep diving on how to modernize your site's BD strategy. Jennifer, welcome.
Jennifer LarkinThanks, Lauren. I really appreciate that. I'm so glad to be here today. so, I lead business development and commercial strategy here at M3, and, I've been in the healthcare industry for over 20-plus years. started my career early on in the pharma side calling directly on physicians and learned quite a bit over 10 years of launching new drugs and switched into early phase development and worked on the early phase discovery side for over eight years. And it wasn't until probably more like six years ago or so that I transitioned over onto the clinical research side, working in the sites industry, and I've been on that side of the business for the last six years.
Lauren StockwellThat is such an amazing journey, kinda coming from the sponsor perspective and then transitioning into the site. What would you say, in your own work history that you brought from that sponsor perspective into your experience at site now?
Jennifer LarkinYeah. I think early on in my career from a pharma perspective, learning and understanding all of the hard yards it takes to get a drug to market is huge. And I have never had a scientific background, but I've had to go through so many trainings to understand, a patient, information sheet and understanding the trial and what's required and all of the side effect profiles. And so I think a lot of that has helped me to understand a protocol and to be able to quickly assess, is this particular study a good fit for a site? In the end, I think all of my background has really helped just prepare me better to understand what it takes to get a study to run effectively at a site.
Lauren StockwellYeah. Absolutely. So take a moment and walk me through what a modern site's BD function actually does on that day to day, right? What's on that list now that- maybe wouldn't have been five years ago?
Jennifer LarkinYeah. Gosh, Lauren, we do so much on the daily our BD team. So if you sat with my BD team for a week, most of what you'd see isn't just prospecting and phone calls. It's data intelligence work. It's account planning and pipeline management, all with client contact woven throughout. so direct client contact is still a daily constant. It's just one piece of the job. So regular meetings, calls, and emails with sponsors and CROs happen every day and we should be in front of our clients on the regular to stay on top of mind. but I'd say years ago, that relationship contact was probably most of the daily job. But today It's one input alongside several other daily activities that just didn't used to have a more formalized structure. I'd say a large share of the week is data intelligence gathering. And that really means evaluating sponsor pipelines, prospecting, and mining data intelligence platforms. This actually allows us to see what's actually coming down the pipeline when they might be starting, and then it helps us to identify the right contacts to connect with once we know where the opportunities are. And the reality is data intelligence and AI platforms have really changed the game in recent years. They give us access and insights into market trends and show us potential studies that are coming. And then compared to years ago, where we relied on sponsor websites for pipeline intel and client conversations and what they were actually willing to share with us, and now it's structured near daily research activity that happens before a single call is made, and it becomes part of the pre-call planning process, I think another important part of the BD process also is qualifying new opportunities for fit before they're pursued. And when an opportunity is identified, part of that day-to-day is evaluating If it's the kind of study and therapeutic area that aligns well with our site capabilities rather than just blindly pursuing every opportunity with equal effort. This step happens constantly and on every opportunity that comes across the desk so we're not wasting valuable time on studies that we just can't support. Another key Activity is account plan development, and for me this is huge and I can't state it enough. It should be done as a regular recurring activity and not a once a year exercise. So building and maintaining account plans should be built into the weekly rhythm, not just something that happens once and gets reviewed yearly or forgotten about until next year when you receive your new sales target. This starts with documenting the history and current status and overall health of each client building out a relationship map, like an org chart tree that shows who we know and if we're in front of the right decision makers running a SWOT analysis on each of the accounts, and then tracking the sponsor's pipeline alongside any specific action steps that will help to grow the account. I think another daily BD task is pipeline maintenance and pushing opportunities through the funnel. Every opportunity In the pipeline needs to stay current with the latest information, and someone has to actually push those forwards. And so active management of the funnel stage by stage is daily work and, not just a monthly pipeline review. And also I think Task and follow-up management keeps all of the above from falling through the cracks. So with multiple accounts, opportunities, and stages moving at once, a meaningful part of the day is assigning tasks and tracking next steps, so follow-ups owed, specific requests from clients, action items from the last call, so nothing sits unanswered. And the reality is this is very unglamorous work, but it's what actually keeps a lean team's pipeline moving instead of stalling. Also I think feasibility itself has grown into a substantial data-heavy deliverable that occupies real time by the BD each week. Sponsors expect a data-backed feasibility response, including patient landscape and real world evidence data, and this is gonna be delivered quickly and not just a gut feel estimate that shows up weeks later That expectation has turned feasibility from a quick ops handoff into a genuine BD-driven task. So validating patient populations with real data, building in what makes a specific PI insight stand out, and attaching an actual recruitment plan to the number all before it goes back to the sponsor is now part of BD's workload. And as an example, our partnership with Cardea Health it's an AI-driven patient matching platform. This lets us validate Patient populations before a feasibility response ever goes out. And it supports our three-day average turnaround for feasibilities. And then you combine that with EMR data access through our 30-plus community physician BAA network. It gives sponsors a real-world evidence-based patient count upfront, and that number just doesn't tell them how many patients could qualify for a protocol. It actually helps inform them how many sites they actually might need to hit enrollment targets. We also build in golden nuggets, which is, essential information about each PI and site, like specific strengths and credentials that set them apart. And our in-house marketing and patient recruitment team builds a custom recruitment strategy alongside the response so that the number, the differentiation, and the plan hit all together and arrive all at once And finally, feasibilities shouldn't move forward without a cross-functional sign-off. I think operationally this is super important. Feasibilities only get submitted once BD, operations, and the investigator have all confirmed real capacity and capability. And there should be a confirmatory check after that first site qualification visit to catch any new potential information or changes in the IE criteria protocol before the site is locked into that study. So Coordinating that alignment, chasing down the right people, getting a real answer is not just a rubber stamp, is also a regular part of BD's work week.
Lauren StockwellHow many hats does your team wear? Clearly, you have this process figured out, and you've really tuned into the skillsets and to the needs across what a functional BD team does. So I genuinely appreciate you sharing M3's kinda secret sauce, if you will. I guess when talking about that secret sauce and when looking at how other sites may approach BD, what do you see as opportunities for growth, right? If I'm a site listening to this and I want to improve or lean into some of the practices that M3 Wake has been able to enact where do you see those opportunities of growth happening?
Jennifer LarkinYeah. Great question. So not all BD activity delivers equal return, especially for a lean team, right, or a small team. And some sites may not necessarily be measuring what really matters. from my perspective BD can tend to prioritize relationships instead of pipeline fit. And don't get me wrong, a, a relationship is a real asset, but it isn't predictive of future business on its own. The stronger question is where the current and future business actually is, and whether the site is therapeutically aligned to support it. when I took over the commercial team here at Wake earlier this year, one of the first things I did was reevaluate our client list. So the prior tiering structure here was based mainly on whether there was a relationship with a client or not. So I re-tiered every sponsor and CRO on pipeline compatibility, current and future pipeline, therapeutic alignment, and relationship status altogether to give it an appropriate tiering and ranking structure. Cause the reality is a longtime client contact whose pipeline is either all early discovery or where we can only support one of 10 programs, doesn't really warrant the same time investment as a sponsor whose pipeline matches or maps more closely to what our sites can deliver. And it has to be revisited regularly, right? Because pipelines and programs shift all the time. a strongly aligned account today could look very different in six months to a year down the line I think another pitfall I see is BD chase every opportunity instead of qualifying it first. This is another hot button for me. Not every inbound opportunity deserves BD's full attention. And that has to be decided early before the team invests hours into a feasibility response. Real qualification means doing the due diligence. Review the protocol and IE criteria to confirm therapeutic and operational fit. Confirm the site has patient access for that population and can enroll it successfully. And then look at the timing of the study and whether that fits with the site's current capacity. And also, a step that can easily be skipped is to check whether the company itself has the funding to actually execute the program. additionally, I think also sometimes BD can fall in the trap of measuring How busy they are by volume and not whether they're actually winning. So Counting the number of RFPs answered tells you the team is active. It doesn't tell you whether the funnel is actually converting or whether what's coming is even a good fit to begin with. I think tracking proposal-to-award conversion reframes the question from are we busy to are we winning? so I think the, the right KPIs go deeper than a single win rate. look at how many feasibility questionnaires are actually converting to site qualification visits How many of those SQVs are converting to awards? Each of those conversion points tell you something different about where the funnel is actually breaking down and where a lean team should be spending its time instead. And I also think that BD and site teams can default to focusing on their same top performers instead of distributing opportunities across the network or to other PIs at the same site. So in a multi-site network, it's easy to keep sending opportunities to the same three sites that always deliver, but that leaves capacity and revenue unused elsewhere. So Regularly evaluating pipeline and capacity across the full network keeps growth more evenly distributed instead of concentrated in only a few handful of sites. And I think from an operational perspective, a couple final points. Sites sometimes let BD estimate instead of pulling it from real operational data. So qualify before you commit only works if the capacity read behind it is accurate. So coordinator and PI caseload, current enrollment load, and staff bandwidth are operational data, not a BD estimate. using that real signal is what makes a yes or a no back to the client credible. And I think lastly, another habit or an opportunity for improvement is BD stops measuring the moment the study is contracted. So proposal-to-award conversion tells you if you're winning. It doesn't tell you if what you promised actually happened. so time from award to patient enrolled, screen fail rates, retention rates are the numbers that determine whether a sponsor can come back, will come back, and most sites usually never look at them as a BD metric. And I think that it truly is a BD metric we should be focusing on
Lauren StockwellWhat a wonderful insider perspective from that kind of point, right? I think it's so important that we follow that life cycle of that lead, if you will- and are able to articulate that data across the board to, again, create a next generation of opportunities So talking about that and the way that you partner with these sponsors and CROs, what makes a sponsor CRO trust a site as a true partner, right? Instead of just another vendor on their list of people.
Jennifer LarkinYeah. I, I think clients want reliable partners where they can count on predictability of performance. The goal isn't just to do more, it's to do the right things at the right cadence for the relationships that matter most, and to be honest and transparent the whole way through. I think first, be willing to say no. I know knowing when to decline a study and giving specific reasons why it's not a fit builds more trust with a sponsor than stretching to say yes and then underperforming. I think it signals a site understands its own limits, which is exactly what the sponsor wants to know before they commit a study to that site. We'll decline a study where we lack genuine patient access or a required vendor relationship, or maybe the PI or site just doesn't have quite the right experience to deliver. And we'll tell the sponsor exactly why, rather than let that study underperform. I mean, we don't want goose eggs on our records And sponsors remember which sites were straight with them upfront. second, the relationship should be a two-way investment, not a one-way pitch from us to them. A real strategic partnership means mutual investment, and that means the sponsor or CRO is willing to share pipeline visibility and, bring the site in early whether that's like during protocol development or in the RFP profit process, rather than, only at site selection stage. So we build these types of partnerships through regular touch points. We give sponsors and CRO partners, direct access to our operational leaders and our PIs for protocol feedback and operational feedback and sharing our site information, historical performance metrics, and retention rates candidly. I think that transparency is what turns an account from transactional to genuinely partnered. And another area is standing out for specific reasons, not just like strong potential enrollment data. So Enrollment data gets a site onto the shortlist to take a look at and to be able to create a feasibility response, but it doesn't say why that site is the right choice on the list. sharing the particular strengths and credentials that differentiate a site, like the golden nuggets of information I mentioned earlier if you share that alongside the enrollment numbers, it builds credibility and confidence that they've chosen the right sites for the study and I think from an operational perspective, consistency across a network is its own trust signal. So for a multi-site organization like M3 Wake sharing, our shared SOPs, consistent contracting and common systems for tracking enrollment mean a sponsor can trust a multi-site award the way they trust one strong site. So that reliability at scale is something a purely transactional vendor relationship can't offer. Additionally, transparency doesn't end at award. It continues throughout the whole life of the study. So a true partnership, in my mind, doesn't stop being transparent once the study starts. It's Proactively flagging an enrollment pace issue to a sponsor before a monitor catches it, as an example. It's what fewer surprises look like in practice, not just at the pitch stage. And again, predictability of performance is the key here. And I think lastly In a strong partnership, BD is everyone's job, not just the BD team's. Every interaction a sponsor or a CRO has with the site, a CRA's responsiveness, a, a monitor's follow-through, an MSL touchpoint, even the site's visibility into its own community, this all shapes whether the sponsor wants to bring that next study to that site. so treating BD as one department's responsibility kind of leaves engagement capacity on the table, that no amount of added headcount can replace. And really, this is genuinely a mindset shift where we've been deliberately driving across the organization helping site staff understand that the quality of their everyday engagement with sponsors and CROs that itself it's business development and not just something separate from their role
Lauren StockwellIt's a culture of ownership, right? Across the entire organization, and really- embedding that culture into the entire, entire place, right? Whether you're a research assistant and it's your second day on the job, or you're a PI overseeing an entire site or a site manager, any interaction counts as business development. Yeah. So I appreciate that. Yeah. It absolutely impacts the relationship overall. And I guess my final question for you, and I really am curious, you keep mentioning these golden nuggets, right? And- these bits of information, and you've talked about a few of those points. And, you know, some of the sites listening on the line don't always have access to the kind of market research that M3 Wake is capable of running and, and being able to access. What should they be tracking or asking their own network to get some of that same visibility that M3 is getting?
Jennifer LarkinSo you don't need a data platform to start. I think what you need is a living account plan, a, a habit of asking directly and the discipline to actually look at your own numbers. So first, I'd say track your own conversion funnel, not just the wins. So how many feasibility questionnaires convert to site qualification visits? How many of those convert to awards? That alone shows where a funnel is breaking down with no special tool required. and it reframes the question from how much are we doing to what's actually working. I think second, build a living account plan for each key relationship. An effective account plan should include evaluation of the relationship's history and therapeutic alignment, a relationship map to understand who you know and whether you're in front of the right people and the current pipeline and its timing. And it should be reviewed regularly at least quarterly, because people leave, companies get acquired, and programs get canceled constantly. so a tier one account that started at the beginning of the year could easily become a tier three or four midyear or by the end of the year if the therapeutic alignment shifts. So third, ask directly for pipeline visibility. Pipeline visibility isn't something that only large networks get access to. It's something sponsors and CROs will share with sites that they've shown reciprocity with transparency. Ask what's coming next. Don't just discuss the protocol that's in front of you. It's Really a habit that any size team can build into every relationship touchpoint. And if you don't have access to data intelligence platforms like Synapse Wire or Global Data, there are plenty of other sources to get information from, such as industry newsletters like FierceBiotech, Biopharm BioSpace, PharmaVoice of course LinkedIn and clinicaltrials.gov. And also use a CRM to make management systematic. Effective use of a CRM in daily workflow helps streamline prospecting, follow-up, meeting notes next steps on open opportunities. It's easy for a lean team to lose track of where things stand without one, even with the strongest relationship. And lastly, track delivery, not just award. time from award to first patient screened, as well as screen fail and retention rates and enrollment targets met are what determines whether a sponsor comes back. Over time, that's kind of its own form for market intelligence. It tells a site which types of studies and sponsors are the best fit based on real outcomes rather than guesswork.
Lauren StockwellBeautiful. Jennifer, thank you so very much. This has been such an incredibly insightful conversation on how listeners can modernize their BD strategy. Thank you very much for your time today. You know, SCRS really proactively supports site sustainability, and we're so excited and honored to partner with individuals like yourself to do just that. thank you to all of our members listening on the line, and we hope that each of you will join us back here again for our next SCRS Talks podcast. Thank you, Jennifer.
Jennifer LarkinThank you, Lauren